Gossamer Bio, Inc.
GOSSHealthcare|Biotechnology|US
$9.77
+0.35 (+3.72%)
DCF Value
$117.58
Cash / Share
$20.66
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06274801 Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | Pulmonary Arterial Hypertension | P3 | Recruiting | 330 | Open-label | Seralutinib |
| NCT07181382 Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Pulmonary Hypertension Associated With Interstitial Lung Disease | P3 | SUSPENDED | 480 | RCT, Double-blind | Placebo, Seralutinib |
| NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) | Pulmonary Arterial Hypertension | P3 | Completed | 390 | RCT, Double-blind | Placebo, Seralutinib |
| NCT03956862 GB001 in Adult Participants With Chronic Rhinosinusitis | Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | P2 | Completed | 97 | RCT, Double-blind | GB001, Placebo |
| NCT04556383 A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC) | Ulcerative Colitis | P2 | Terminated | 236 | RCT, Double-blind | GB004, Placebo |
| NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | P2 | Terminated | 74 | Open-label | GB002 (seralutinib) |
| NCT03683576 GB001 in Adult Subjects With Moderate to Severe Asthma | Asthma | P2 | Completed | 481 | RCT, Double-blind | GB001, Placebo |
| NCT04456998 GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) | Pulmonary Artery Hypertension | P2 | Completed | 86 | RCT, Double-blind | GB002 (seralutinib), Placebo |
| NCT03473236 Phase 1A Safety Trial of Inhaled PK10571 (GB002) | Safety Issues | P1 | Completed | 66 | RCT, Double-blind | GB002, Placebo |
| NCT03860896 GB004 in Adult Subjects With Active Ulcerative Colitis | Ulcerative Colitis | P1 | Completed | 34 | RCT, Double-blind | GB004, Placebo, GB004 |
| NCT05242146 GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma | CNS Lymphoma | P1 | Terminated | 12 | Open-label | GB5121 |
| NCT03926793 Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | P1 | Completed | 8 | RCT, Double-blind | GB002, Placebo |
| NCT04060342 GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma | P1 | Terminated | 61 | Open-label | GB1275, nab-paclitaxel and gemcitabine, pembrolizumab |